Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 612 matching trials from the live ClinicalTrials.gov search.
Conditions
McCune-Albright Syndrome, Fibrous Dysplasia, Intraductal Papillary Mucinous Neoplasm, Diabetes Mellitus
Interventions
Hyperinsulinemic Euglycemic Clamp and 2H20, Hyperglycemic Clamp, Oral Glucose Tolerance Test
Procedure · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Disorder of Glucose Regulation
Interventions
Sitagliptin-Metformin, Metformin, Placebo pill
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Rosiglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
35 Years and older
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
67
States / cities
Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 63 more
Completed Not applicable Interventional Results available

Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS

NCT03717935
Conditions
Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
Interventions
Essential Amino Acid (EAA) Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Racial Differences in Vagal Control of Glucose Homeostasis

NCT02365285
Conditions
Obesity
Interventions
Galantamine, Placebo Oral Capsule, Intralipid, Heparin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 4 Interventional Results available

Simplified Insulin Protocol Using Lantus in Elderly

NCT01480843
Conditions
Diabetes
Interventions
Glargine
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
70 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
85
States / cities
Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more
Conditions
Impaired Glucose Tolerance
Interventions
All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
Lapatinib, Topotecan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Diabetes Mellitus, Type 2, Non-Insulin-Dependent Diabetes Mellitus
Interventions
GSK189075 oral tablets, GW869682 oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Diabetes Mellitus
Interventions
Alogliptin and insulin, Insulin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Phoenix, Arizona • Anaheim, California • Artesia, California + 42 more
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
54
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more
Conditions
Type 2 Diabetes Mellitus
Interventions
insulin aspart, insulin detemir
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting No phase listed Observational Accepts healthy volunteers

Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot

NCT06184373
Conditions
Gestational Diabetes, Hyperglycemia
Interventions
Continuous glucose monitor, Oral Glucose Tolerance Test, Hemoglobin A1c
Device · Diagnostic Test
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Gestational Diabetes
Interventions
Screening for diabetes with 1-hour GCT and HbA1
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin 10 mg, Matching Placebo for Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 74 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
27
States / cities
Huntsville, Alabama • Burbank, California • Chula Vista, California + 22 more
Completed Phase 2 Interventional Results available

Energy Metabolism in Thyroidectomized Patients

NCT04782856
Conditions
Thyroid Goiter, Hypothyroidism, Thyroid Cancer
Interventions
Levothyroxine, Liothyronine, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 89 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions
Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care
Other · Diagnostic Test
Lead sponsor
Region Skane
Other
Eligibility
18 Years and older
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Alcohol Use Disorder
Interventions
Suvorexant 10 mg, Placebo
Drug · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dopamine and Insulin Resistance

NCT00802204
Conditions
Obesity
Interventions
PET scan, Oral glucose tolerance test, MRI, Psychological scales to assess attitudes and behaviors related to eating and quality of life, Caloric Restriction
Radiation · Procedure · Behavioral + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metformin Compared to Glyburide in Gestational Diabetes

NCT00965991
Conditions
Gestational Diabetes
Interventions
metformin, Glyburide
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
13 Years and older · Female only
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Terminated Phase 2 Interventional Results available

Vandetanib to Treat Advanced Kidney Cancer

NCT01372813
Conditions
Advanced Clear Cell Renal Carcinoma
Interventions
vandetanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Not applicable Interventional Accepts healthy volunteers

PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes

NCT02282423
Conditions
Diabetes, Obesity
Interventions
Pre-study dietary and exercise instruction., Screening examination and oral glucose tolerance test, Euglycemic clamp, VO2max., Acute exercise bout, Percutaneous needle muscle biopsies
Behavioral · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 59 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Completed Not applicable Interventional Accepts healthy volunteers

Snooze Control: Sleep Duration & Glucose Metabolism

NCT02583750
Conditions
Glucose Metabolism Disorders
Interventions
OGTT after deprived sleep first, OGTT after sufficient sleep first
Behavioral
Lead sponsor
Xuewen Wang
Other
Eligibility
18 Years to 25 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Columbia, South Carolina